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Why is apoptosis important to clinicians?
Because its mechanisms are being used to develop drugs
Apoptosis—programmed cell death—was discov›ered in 1972,1 and now that it approaches its30th birthday its clinical importance is
becoming clear. The excitement of apoptosis for
doctors lies in the clinical implications of perturbed›
restored control of cell number and function through a
balance between cell death and cell survival.
Apoptosis may become disrupted in two major
ways, and, as predicted over 20 years ago,2 each seems
to be associated with different types of disease.
Inappropriate activation of the apoptotic process leads
to disorders associated with pathological loss of cells—
such as the immune defect in AIDS and possibly neu›
rodegenerative diseases. In contrast, inadequate apop›
tosis, leading to inappropriate cell survival, leads to
diseases associated with excessive accumulations of
cells—such as cancer, chronic inflammatory conditions,
and autoimmune diseases.
The defect in immunity associated with AIDS is the
result of a profound reduction in the population size of
CD4+ T helper cells caused by excessive apoptosis;
this occurs even at comparatively low levels of HIV
infectivity, so that many non›infected T cells must also
be lost. The exact mechanisms are uncertain but may
include transfer of regulatory viral gene products (such
as HIV›1 Tat) from HIV infected cells to bystander T
cells, rendering them susceptible to T cell receptor›
induced, CD95›mediated apoptosis.3 Neurodegenera›
tive disorders have also attracted attention,4 but the
relative contribution of apoptosis to neurone cell loss
in Alzheimer’s disease is uncertain because not all
degenerating neurons show clear features of apoptosis
(which are extraordinarily difficult to quantify in situ,
especially in chronic disease processes).
Nevertheless, an increasing body of indirect
evidence suggests that neuronal cell apoptosis may be
triggered by amyloid â and other neurotoxic abnormal
protein structures or aggregates in Alzheimer’s and
other adult neurodegenerative diseases (including
Huntington’s chorea, Parkinson’s disease, and amyo›
trophic lateral sclerosis).4 A central role for amyloid â
protein is supported by the effects of genetic mutations
that cause Alzheimer’s disease, all of which predispose
to amyloid deposition. It is also supported by the
observation that amyloid â can exert neurotoxic effects
in vitro and in vivo, and by mechanisms which may
involve the generation of intracellular oxidative stress
and increases in calcium ions, both of which can trigger
apoptosis in susceptible cell types.4 These effects may
be induced by amyloid â cross linking receptors for
advanced glycosylation end products (RAGE), amyloid
precursor protein (APP), or a receptor called P75, all of
which can trigger neuronal apoptosis. In situ, however,
the situation is much more complex, and other
resident cells may play important roles. For example,
microglial activation, which occurs in response to local
amyloid plaque formation, is known to stimulate secre›
tion of the tumour necrosis factor á and other factors
that can induce apoptosis in vitro.
Many therapeutic approaches to counter inappro›
priate apoptosis have been mooted. Since proteolytic
enzymes called caspases are critical to the control of
apoptosis (they reorganise the dying cell from within
and make it ready for safe clearance by phagocytes),
several pharmaceutical companies are developing
potent and specific caspase inhibitors. None is yet suit›
able for use in humans. Nevertheless, non›specific cas›
pase inhibitors have shown great promise in in vitro
and murine models of inappropriate neuronal
apoptosis.5
Cancer, on the other hand, occurs when mutations
affect the control mechanisms of apoptosis and cell
survival. Indeed, the bcl›2 gene was identified as block›
ing apoptosis because of its abnormal overexpression
in follicular lymphoma. Furthermore, mutations in p53
(a protein believed to be the “guardian of the genome”)
prevent the deletion, by apoptosis, of cells with
damaged DNA, so that tumours develop. Inflammatory
disorders such as rheumatoid arthritis may also reflect
prolonged survival of leucocytes that are normally
programmed to die by apoptosis.
In both cases the therapeutic objective is to remove
unwanted cells. The treatment of certain lymphomas
by antisense oligonucleotides (which block gene
transcription) to bcl›2 is a realistic prospect. Further›
more, death›inducing cytokines of the tumour necrosis
factor family, such as TRAIL, are showing promise in
colon cancer. Recent evidence has shown that normal
and cancerous cells show major differential susceptibil›
ity to apoptosis stimulated by TRAIL.6 Moreover, death
receptor›mediated apoptosis may be particularly valu›
able in cancer treatment since it is likely to be
independent of p53 status (which is corrupted in 50%
of all primary cancer tumours) and it is also largely
independent of Bcl›2.7 Nevertheless, caution is
necessary, since excessive generalised activation of cell
death pathways can trigger a fatal form of haemor›
rhagic liver necrosis.
Thus apoptosis is no longer an arcane pathological
phenomenon. Instead, the molecular basis of pro›
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grammed death and cell survival is one of the most
vibrant areas of laboratory research. Clinical trials are
imminent, so we predict that this promising youngster
will show many achievements by its 50th birthday.
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Depression, suicide, and the national service
framework
Suicide is rare and the only worthwhile strategy is to target people at high risk
The National Service Framework for MentalHealth1 seeks to cut the suicide rate by a furtherfifth from Health of the Nation targets.
Standard 7, preventing suicide, advises about health
promotion and improved services, including assess›
ment and treatment of depression in primary care and
assessing risk among individuals at greatest risk. Will
these improvements deliver results? Are there other
more promising strategies?
It is widely assumed that early and accurate identi›
fication of depressive episodes will reduce suicides.
This follows from a belief that suicide is a common
adverse outcome in depressive disorders: a 15%
lifetime risk is often cited. However, clinical experience
and population based studies challenge this view. Every
week 10% of the UK population aged 16›65 report sig›
nificant depressive symptoms, and one in 10 of these
admits to suicidal thinking.2 But fewer than two people
in a million will kill themselves. A typical primary care
group of 100 000 expects 10 suicides a year.1
Depressive disorders are therefore common, while sui›
cide remains rare.
The estimate of 15% lifetime risk of suicide
emerged from a review of 17 studies of depressed
patients, mainly in secondary care, all before 1970.3 A
recent meta›analysis revises the figure to 6%,4 but this
may still be biased towards recurrent inpatients at terti›
ary centres.5 A study from the United States sharpens
the focus, describing 62 159 person years’ follow up for
35 546 insured patients treated for depression.5 Risk of
suicide declined from 224 per 100 000 patient years
for inpatients to 64 for outpatients, 43 for those receiv›
ing antidepressants in primary care, and 0 for those
without drug or secondary treatment. These estimates
are much lower and relate to treatment history.
What does this mean for the national service
framework strategy? Better quality primary mental
health care for all depressed patients can reduce
disability and improve functioning, but the result is
unlikely to be a visible and cost effective reduction in
the rare phenomenon of suicide.
The second approach in the framework of improv›
ing risk assessment must be linked to intervention, but
only in genuinely high risk groups to avoid prohibitive
expense and patient inconvenience. The US findings
offer little encouragement. Even with an entirely effec›
tive programme, 400 inpatients would require inter›
vention to prevent one suicide a year. In general
practice the number needed to treat would be almost
5000. The national confidential inquiry into suicide6
found that 15% of those who did kill themselves had
already been identified as being at moderate or high
risk. A 100% improvement in risk assessment would
identify only 30% of future suicides, and effective inter›
ventions would still be needed. Geddes argued in the
BMJ that suicide is unlikely ever to be a realistic
outcome measure for randomised trials and for high
risk groups more common outcomes such as self harm
should be considered.7 The national service framework
strategy to “ensure that staff are competent to assess
the risk of suicide among individuals at greatest risk”
begins to look threadbare at the clinical level.
Clinicians and researchers are challenged to
identify a group with genuinely high suicide risks and
to study intermediate outcomes common enough to be
influenced by individual and team interventions. The
performance indicators in the national service
framework do include a promising intermediate candi›
date, readmission of those with severe mental illness.
We can predict groups of depressed inpatients with a
50% risk of readmission within two years. These
include those with: four previous admissions,8 a family
history of suicide or admission for depression, and
treatment with electroconvulsive therapy.9 Recurrence
of severe depressive disorders multiplies the cumula›
tive risk of suicide, as admission and discharge are
periods of higher risk. The long term risk of suicide in
this group is likely to exceed 15%—for example, the
confidential inquiry showed that 22% of patients who
committed suicide had had five or more admissions.6
We can therefore specify a common adverse
outcome—readmission—in a group who may be at a
relatively high risk of suicide. Proved interventions to
prevent recurrence of depression exist—for example
cognitive behavioural therapy and interpersonal psy›
chotherapy,10 but these are not routinely available in
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